Leanbio invests additional 20m euros in GMP biologics plant in Barcelona to increase production capacity

Leanbio, a company providing comprehensive development and manufacturing services for biological products in the pharmaceutical and biopharmaceutical sectors, is adding an additional 20m euros in investment to its plant, currently under construction, in Sant Quirze del Vallès, Barcelona.

Spanning over 3500m2, the facility will house three production lines capable of manufacturing recombinant proteins and antibodies in different expression systems, as well as plasmid DNA and messenger RNA for advanced therapies within the biopharmaceutical sector. It will also include development laboratories, scaling areas, pilot production plants, and quality control.

The project has been selected as a Vanguard Health PERTE initiative, aimed at promoting innovative technological projects in the pharmaceutical sector that also meet strict sustainability criteria.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news